

SeQuent Scientific announces Q1FY16 Financial Results

Q1FY16 revenues at Rs1484 million,
EBITDA Margins at 12.7%, up by 600 bps

Continuing Operations grew by 45% over Q1FY15

Bangalore, July 30, 2015: SeQuent Scientific Limited, a leading Integrated Pharmaceutical Company with business across Animal Health, Niche Human APIs & Analytical Services today announced its financial results for the first quarter ended June 30, 2015 (Q1FY16)

Financial Highlights

Q1FY16 (Quarter ended June 30, 2015)

- Operating revenue was **Rs1484 million** as compared to **Rs1127**million in Q1FY15, up by 32%. Continuing operations* grew by 45% over Q1FY15.
- EBITDA at **Rs188 million** as compared to **Rs.74 million** in Q1FY15
- EBITDA Margin at **12.7%** for Q1FY16 as against **6.6%** in Q1FY15

**Continuing operations excludes revenues from Speciality Chemicals business, which the Company divested in August 2014.*

Commenting on the Company's performance for Q1FY16, **Manish Gupta, Managing Director** said, "We are pleased to close this quarter on a robust note, with the Company returning to profitability. Our improved financial and operating performance demonstrates that strategic directions we have taken over the last two years are bearing fruit."

Business Review & Strategy

- Successful GMP inspection of Provet's manufacturing facility from Turkish authorities
- Robust performance in cattle business in India
- Fully operationalized Vizag facility (API) and discontinued operations at Ambernath
- Filed 3 DMFs

Corporate Actions

Fund raising:

- The Company raised Rs. 4000 million through Qualified Institutional Placement, which was subscribed by quality, long-term investors who endorsed the vision of the Company of being a Power House in the Global Animal Health Space.
- The Company also raised Rs.1045 million through preferential issue to Promoters / Non Promoters.

Consolidation of shareholding in Alivira Animal Health Limited ('Alivira')

- During the Quarter, the Board approved buyout of entire minority interest in Alivira, a subsidiary of the Company. Post such acquisition, Alivira will become a wholly owned subsidiary of the Company, which will enable consolidation of 100% of the animal health business

About SeQuent Scientific Limited

SeQuent Scientific Limited ("SeQuent") is a leading Integrated Pharmaceutical Company with business across Animal Health, niche Human APIs & Analytical Services.

SeQuent through its subsidiary, Alivira Animal Health Ltd. is emerging as a powerhouse in the global Animal Health business with presence in both the APIs and Formulations, built on a platform of superior quality and compliance.

Sequent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA amongst others.

SeQuent's vision is to become an integrated global leader in the Animal Health Ingredient space, manufacture niche molecules and be a specialized Human APIs resource for our customers.

The Company is listed on the Bombay Stock Exchange and headquartered in Mumbai, India.

For Queries, please contact

N Kannan

Investor Relations
Tel: +91 80 67840751
kannannatraj@airtelmail.in

Kannan P R

Chief Financial Officer
Tel: +91 80 67840327
Kannan.pr@sequent.in

Ankit Gupta

Christensen Investor Relations
Tel : +91 22 42150210
ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited
301/A, 'Dosti Pinnacle',
Plot No.E7,Road No. 22,
Wagle Industrial Area, Thane (W),
Maharashtra, India

Company Information

CIN: U24110MH2002PLC136868
BSE Code:512529
ISIN:INE807F01019
REUTERS: SEQU.BO
Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.